---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000023"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:20:17.010456+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M

## Summary
- Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.
- Exclusive global license with Vanda for imsidolimab: $15M upfront, up to $35M milestones, 10% royalty on net sales.
- Cash and investments $420.8M at Dec 31, 2024; cash runway reiterated through year-end 2027.
- Collaboration revenue from GSK Jemperli milestones $43.1M in Q4 and $91.3M in FY2024; Jemperli 2024 sales $598M (>200% growth).
- Net loss $21.8M in Q4 ($0.72 loss per share) vs $42.2M in prior year; FY2024 net loss $145.2M ($5.12 per share).

## SEC filing metadata
- accession: 0001370053-25-000023
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/0001370053-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/anab-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000023
- JSON: https://secwatch.observer/filing/0001370053-25-000023.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.